Drug Profile
V 526
Alternative Names: MRKAd5+6 Trigene; V526Latest Information Update: 30 Dec 2014
Price :
$50
*
At a glance
- Originator Merck & Co
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 15 Feb 2007 Phase-II clinical trials in HIV infections in USA (IM)